New Metabolomics Kit Enables Use with Specialized Mass Spectrometer
By LabMedica International staff writers Posted on 26 Mar 2013 |
Image: The new “AbsoluteIDQ p150” metabolomics kit (Photo courtesy of Biocrates).
A state-of-the-art metabolomics-based research kit has been specially designed for use with a triple stage quadrupole mass spectrometer, enabling additional laboratories to use such kits.
Biocrates Life Sciences AG (Innsbruck, Austria) introduced “AbsoluteIDQ p150,” the new edition of its well-established line of metabolomics-based research kits. The kit has been available for use with AB Sciex and Waters mass spectrometry systems, and has now been designed to also run on Thermo Scientific’s “TSQ Vantage” Triple Stage Quadrupole Mass Spectrometer, enabling more research labs to harness the power of targeted metabolite quantification with a ready-to-use kit system. Combined with a robust new ion source, second-generation ion optics, and hyperbolic quadrupoles, the “TSQ Vantage” mass spectrometer delivers both higher sensitivity and lower chemical noise.
AbsoluteIDQ p150 provides extensive metabolic information from a single targeted assay, quantifying 158 metabolites using a FIA-MS/MS method. It features the proprietary “MetIDQ” software, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice with a cost-effective solution to measure endogenous metabolites under quality-controlled conditions in a researcher’s own laboratory. The Biocrates AbsoluteIDQ kits have been successfully applied in many different areas, including oncology, endocrinology, diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research. Biocrates mass spectrometry-based, standardized metabolomic kits provide multiplexing potential and superior accuracy and precision.
Related Links:
Biocrates
Biocrates Life Sciences AG (Innsbruck, Austria) introduced “AbsoluteIDQ p150,” the new edition of its well-established line of metabolomics-based research kits. The kit has been available for use with AB Sciex and Waters mass spectrometry systems, and has now been designed to also run on Thermo Scientific’s “TSQ Vantage” Triple Stage Quadrupole Mass Spectrometer, enabling more research labs to harness the power of targeted metabolite quantification with a ready-to-use kit system. Combined with a robust new ion source, second-generation ion optics, and hyperbolic quadrupoles, the “TSQ Vantage” mass spectrometer delivers both higher sensitivity and lower chemical noise.
AbsoluteIDQ p150 provides extensive metabolic information from a single targeted assay, quantifying 158 metabolites using a FIA-MS/MS method. It features the proprietary “MetIDQ” software, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice with a cost-effective solution to measure endogenous metabolites under quality-controlled conditions in a researcher’s own laboratory. The Biocrates AbsoluteIDQ kits have been successfully applied in many different areas, including oncology, endocrinology, diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research. Biocrates mass spectrometry-based, standardized metabolomic kits provide multiplexing potential and superior accuracy and precision.
Related Links:
Biocrates
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples